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Abstract
Obesity is a chronic inflammation with increased serum levels of insulin, insulin-like growth
factor 1 (IGF1), and interleukin-17 (IL-17). The objective of this study was to test a hypothesis
that insulin and IGF1 enhance IL-17-induced expression of inflammatory chemokines/cytokines
through a glycogen synthase kinase 3β (GSK3B)-dependent mechanism, which can be inhibited by
melatonin. We found that insulin/IGF1 and lithium chloride enhanced IL-17-induced expression
of C-X-C motif ligand 1 (Cxcl1) and C-C motif ligand 20 (Ccl20) in the Gsk3b+/+ but not
Gsk3b−/− mouse embryonic fibroblast (MEF) cells. IL-17 induced higher levels of Cxcl1 and
Ccl20 in the Gsk3b−/− MEF cells, compared to the Gsk3b+/+ MEF cells. Insulin and IGF1
activated Akt to phosphorylate GSK3B at serine 9, thus inhibiting GSK3B activity. Melatonin
inhibited Akt activation, thus decreasing P-GSK3B at serine 9 (i.e., increasing GSK3B activity)
and subsequently inhibiting expression of Cxcl1 and Ccl20 that was induced either by IL-17 alone
or by a combination of insulin and IL-17. Melatonin's inhibitory effects were only observed in the
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Gsk3b+/+ but not Gsk3b−/− MEF cells. Melatonin also inhibited expression of Cxcl1, Ccl20 and
Il-6 that was induced by a combination of insulin and IL-17 in the mouse prostatic tissues. Further,
nighttime human blood, which contained high physiologic levels of melatonin, decreased
expression of Cxcl1, Ccl20 and Il-6 in the PC3 human prostate cancer xenograft tumors. Our data
support our hypothesis and suggest that melatonin may be used to dampen IL-17-mediated
inflammation that is enhanced by the increased levels of insulin and IGF1 in obesity.
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Introduction
Melatonin (also known chemically as N-acetyl-5-methoxytryptamine) is an endogenous
indolamine that is synthesized mainly by the pineal gland during the dark phase of circadian
rhythm in mammals, including humans [1]. Melatonin acts through two G protein-coupled
melatonin receptors (MT1 and MT2) on the cytoplasmic membrane [2], a cytosolic
melatonin receptor (MT3) [3], or directly as a free radical scavenger/antioxidant molecule
[4]. Melatonin plays an important role in many physiological and pathological processes,
thus it has been tested in the treatments of a variety of diseases [5]. Among them, melatonin
has been shown to improve the symptoms of inflammatory bowel diseases. The anti-
inflammatory actions of melatonin are mediated through multiple molecular mechanisms,
including down-regulation of inducible nitric oxide synthase and cyclooxygenase, reduction
of pro-inflammatory cytokines and chemokines (tumor necrosis factor-α (TNF-α),
interferon-γ, interleukin-1 (IL-1), IL-6, IL-8, and IL-12), and increase of anti-inflammatory
cytokines (IL-10 and IL-1 receptor antagonist)(see a recent review [6]). We noted that TNF-
α, IL-1, IL-6, and IL-8 are the downstream target genes of IL-17 [7], which led us to
investigate melatonin's action on IL-17 signaling in the present study.
IL-17 (including IL-17A, IL-17F, and IL-17A/F) binds to a heterodimer of IL-17RA/
IL-17RC receptor complex, leading to recruitment of nuclear factor-κB (NF-κB) activator
1(Act1) through SEFIR (similar expression to fibroblast growth factor genes, IL-17
receptors and Toll–IL-1R) domains that exist in IL-17RA, IL-17RC, and Act1 proteins
[8-12]. Act1 is also named as connection of IκB kinase and stress-activated protein kinase/
Jun kinase (CIKS) [13]. Act1 is an E3 ubiquitin ligase that activates tumor necrosis factor
receptor-associated factor 6 (TRAF6) through lysine-63-linked ubiquitination [14]. The
polyubiquitinated TRAF6 activates transforming growth factor –β-activated kinase 1
(TAK1) and subsequently IκB kinase (IKK) complex, leading to activation of NF-κB
pathway that induces transcription of a variety of cytokines, chemokines and growth factors
[13, 15-21]. While the IL-17-driven NF-κB signaling pathway has been clearly defined, it is
not quite clear how IL-17 activates the extracellular signal-regulated kinase ½ (ERK1/2),
thus stabilizing the mRNAs of the IL-17 downstream target genes [22]. In addition, it has
been demonstrated that IL-17 stabilizes downstream C-X-C motif ligand 1 (CXCL1) mRNA
through an inducible kinase IKKi-dependent Act1-TRAF2-TRAF5 complex, which binds to
splicing factor 2 (SF2, also named alternative splicing factor - ASF) and prevents SF2/ASF-
mediated mRNA degradation [23, 24].
Insulin is a hormone produced by the β cells of the pancreas. Hyperinsulinemia occurs in
obesity and type 2 diabetes mellitus with insulin resistance. Under the hyperinsulinemic
status, insulin upregulates expression of growth hormone receptor in the liver, thus
enhancing hepatic production of insulin-like growth factor 1 (IGF1) [25]. Insulin binds to
insulin receptor (IR-A and IR-B) and IGF1 binds to IGF1 receptor (IGF1R). IGF1 can also
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bind to a heterodimer of IGF1R and IR-A (or IR-B). Ligand binding leads to
autophosphorylation of the β subunit of IR or IGF1R, resulting in recruitment of insulin
receptor substrates (IRS) 1 to IRS4 and other adaptor proteins. Consequently,
phosphatidylinositol 3-kinase (PI3K)/Akt pathway and ERK1/2 pathway are activated [26].
One of the major substrates of Akt is glycogen synthase kinase 3β (GSK3B). Insulin-
stimulated Akt phosphorylates GSK3B at serine 9, thus inactivating GSK3B [27, 28]. A
decrease in GSK3B activity leads to reduced phosphorylation of glycogen synthase, thus
glycogen synthase activity is increased, resulting in increased glycogen synthesis.
GSK3B is one of the two GSK3 isoforms (GSK3A and GSK3B) of serine/threonine protein
kinases that are ubiquitously expressed in all cell types. GSK3B is constitutively active and
it phosphorylates more than 50 substrates [29]. Among these substrates, CAAT enhancer
binding protein β (C/EBPβ) is closely associated with IL-17 signaling. IL-17 induces
expression of C/EBPβ and C/EBPδ mRNA and protein [9, 20, 30]. C/EBPβ and C/EBPδ
transcription factors are essential for transcription of IL-17-downstream target genes such as
IL-6 and 24p3/lipocalin 2 [31]. However, IL-17 also initiates a negative feedback
mechanism by activation of ERK1/2 to phosphorylate C/EBPβ at threonine 188, followed by
phosphorylation of C/EBPβ at threonine 179 by GSK3B. Phosphorylation of C/EBPβ
inhibits expression of IL-17-downstream target genes, thus GSK3B negatively regulates
IL-17 signaling through phosphorylation of C/EBPβ [32]. Indeed, inhibition of GSK3
activity by GSK3 inhibitor I can enhance IL-17-induced expression of IL-6, 24p3/lipocalin
2, CXCL5, C-C motif ligand 2 (CCL2), CCL7, and NF-κB inhibitor zeta, whereas
overexpression of GSK3B can inhibit IL-17-induced IL-6-promoter and 24p3-promoter
activities in a mouse stromal ST2 cell line [32]. Therefore, GSK3B functions as an intrinsic
negative regulator of IL-17-mediated inflammatory responses.
Approximately 35% of adult Americans are obese [33]. It is well known that obesity is
associated with type 2 diabetes mellitus with increased serum levels of insulin and IGF1,
and that obesity results in a chronic inflammatory state with increased serum levels of
inflammatory mediators TNFα and IL-6 [34]. Recently, it has been found that serum and
tissue levels of IL-17 are increased in obese mice [35, 36] and humans [37]. Given that
insulin and IGF1 can inhibit GSK3B activity through PI3K/Akt pathway [27, 28], we
hypothesized that insulin and IGF1 might enhance IL-17-induced expression of
inflammatory chemokines/cytokines through a GSK3B-dependent mechanism, which can be
inhibited by melatonin. In the current study, we tested this hypothesis. Our data
demonstrated that insulin and IGF1 indeed enhanced IL-17-induced expression of CXCL1,
CCL20, and IL-6 in the in vitro cultured mouse embryonic fibroblast (MEF) cell lines and
ex vivo cultured mouse prostatic tissues, which was dependent on GSK3B. We also tested
the postulate that melatonin, an endogenous indolamine molecule with anti-inflammatory
actions [6], blocks the action of insulin and IGF1 through inhibition of Akt-mediated
GSK3B phosphorylation.
Materials and methods
Cell and tissue culture
Mouse Gsk3b knockout (Gsk3b−/−) and wild-type (Gsk3b+/+) MEF cells were described
previously [38]. Cells were maintained in Dulbecco's Modified Eagles Medium (DMEM,
Mediatech, Inc., Manassas, VA, USA) containing 10% fetal bovine serum (FBS, Mediatech,
Inc., Manassas, VA, USA) and 100 IU/ml penicillin/streptomycin in a 37°C, 5% CO2
humidified incubator. Six-week-old mice were euthanized by CO2 asphyxiation. Mouse
prostatic glands were dissected out, cut into cubes of approximately 1 to 2 mm3 in size, and
washed three times with phosphate buffered saline (PBS). The prostatic tissues were kept in
60-mm cell culture dishes in serum-free DMEM in the incubator and immediately treated
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with the reagents. The animal studies were approved by the Animal Care and Use
Committee of Tulane University.
Treatment of cells and tissues
Cells were grown in 60-mm cell culture dishes to approximately 90% confluency and
changed into serum-free DMEM for 16 hours prior to the treatments. The cells or mouse
prostatic tissues were treated separately or in combination with 20 ng/ml recombinant mouse
IL-17A (R&D Systems, Inc., Minneapolis, MN, USA), 10 nM recombinant human insulin,
50 ng/ml recombinant human IGF1, 5 ng/ml TNFα, 10 nM melatonin, and/or 20 mM
lithium chloride (LiCl) (Sigma-Aldrich, St. Louis, MO, USA). Insulin, IGF1, melatonin, and
LiCl were added 30 minutes prior to addition of IL-17A in the combined treatments. At
different time points as indicated, the cells or tissues were harvested for RNA or protein
isolation.
Real-time quantitative reverse transcriptase PCR
After 2-hours treatment with IL-17A, the cells and tissues were collected in lysis buffer and
homogenized with a 1-ml syringe connected to a 21-gauge needle. Total RNA was isolated
according to the instructions of RNeasy Mini Kit (QIAGEN, Valencia, CA, USA) with on-
membrane DNase I digestion to avoid genomic DNA contamination. cDNA was made from
total RNA using iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA,
USA). Mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primers were obtained
from Applied Biosystems (Foster City, CA, USA). The PCR primers specific for each
mouse gene are as follows: Cxcl1 Forward (5′-CACCCAAACCGAAGTCATAG-3′), Cxcl1
Reverse (5′-AAGCCAGCGTTCACCAGA-3′), Ccl20 Forward (5′-
AACTGGGTGAAAAGGGCTGT-3′), Ccl20 Reverse (5′-
GTCCAATTCCATCCCAAAAA-3′), Il-6 Forward (5′-
CTACCCCAATTTCCAATGCT-3′), Il-6 Reverse (5′-
ACCACAGTGAGGAATGTCCA-3′). Real-time quantitative PCR (qRT-PCR) was
performed in triplicates with an iQ5®iCycler and iQ™ SYBR® Green Supermix (Bio-Rad
Laboratories, Hercules, CA, USA) following the recommended protocols. Results were
normalized to GAPDH levels using the formula ΔCt (Cycle threshold) = Ct of target gene –
Ct of GAPDH. The mRNA level of the control group was used as the baseline; therefore,
ΔΔCt was calculated using the formula ΔΔCt = ΔCt of target gene - ΔCt of the baseline. The
fold change of mRNA level was calculated as fold = 2−ΔΔCt.
Western blot analysis
Proteins were extracted from the treated cells in RIPA lysis buffer [50 mM sodium fluoride,
0.5% Igepal CA-630 (NP-40), 10 mM sodium phosphate, 150 mM sodium chloride, 25 mM
Tris pH 8.0, 1mM phenylmethylsulfonyl fluoride, 2 mM ethylenediaminetetraacetic acid
(EDTA), 1.2 mM sodium vanadate] supplemented with protease inhibitor cocktail (Sigma-
Aldrich, St. Louis, MO, USA). Equal amount of proteins was subjected to 10% SDS-
polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membrane.
The membranes were blocked with 5% nonfat dry milk in TBST buffer (25 mM Tris-HCl,
125 mM NaCl, 0.1% Tween 20) for 2 hours and probed with the indicated primary
antibodies overnight and then IRDye®800CW- or IRDye®680-conjugated secondary
antibodies (LI-COR Biosciences, Lincoln, NE, USA) for 1 hour. The results were visualized
by using an Odyssey Infrared Imager (LI-COR Biosciences, Lincoln, NE, USA). For
loading control, the membranes were stripped and probed for unphosphorylated proteins
and/or GAPDH. The antibodies used are as follows: rabbit anti-P-Akt (S473), rabbit anti-
Akt, rabbit anti-P-GSK3B (S9), rabbit anti-GSK3B, rabbit anti-P-GSK3A (S21), rabbit anti-
GSK3A, rabbit anti-ERK1/2, rabbit anti-P-STAT3(Y705), mouse anti-STAT3, rabbit anti-P-
IκBα, mouse anti-IκBα, and rabbit anti-P-C/EBPβ (human T235 and mouse T188)
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antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA); mouse
anti-P-ERK1/2, rabbit anti-C/EBPβ, and rabbit anti-p65 antibodies were obtained from Santa
Cruz Biotechnology (Santa Cruz, CA, USA); mouse anti-GAPDH antibodies were ordered
from Millipore Corporation (Billerica, MA, USA).
Tissue-isolated PC3 human prostate cancer xenografts
Fifteen xenograft tumor samples were obtained from our previous study [39]. Briefly, PC3
human prostate cancer xenografts were first grown subcutaneously in nude mice, then,
implanted in nude rats in a tissue-isolated manner, and finally, perfused with human venous
blood for 1 hour as previously described [40]. The blood was drawn from healthy male
donors during the daytime, nighttime, and nighttime after 90 minutes of ocular, bright, white
light exposure at 580 μW/cm2 (i.e., 2800 lux) (so called light-at-night). It has been
previously determined that the physiological levels of melatonin were the lowest in the
daytime (12:50 PM) blood (approximately 12 ～ 14 pg/ml), the highest in the nighttime
(2:00 AM) blood (approximately 55 ～ 60 pg/ml), and intermediate in the nocturnal blood
collected after ocular light exposure (approximately 28 ～ 29 pg/ml) [40]. The collection and
use of human blood was approved by the Institutional Review Board at Thomas Jefferson
University and each donor signed a consent form. Three xenograft tumors per each type of
blood were perfused in situ with the daytime blood, nighttime blood, light-at-night blood,
nighttime blood supplemented with 1 nM of melatonin receptor antagonist S20928, or light-
at-night blood supplemented with 500 pM of melatonin (Sigma-Aldrich, St. Louis, MO,
USA). Approximately 100 mg of each tumor was frozen in liquid nitrogen and pulverized.
Total RNA was isolated by using RNeasy Mini Kit (QIAGEN) according to the instructions.
Real-time quantitative PCR was performed as described above.
Statistical analysis
All experiments were repeated at least three times and consistent results were obtained. The
mRNA levels represent means ± standard deviations of three independent experiments or
three different tumor samples in the PC3 human prostate cancer xenograft study. The
Student's t test was used to analyze the quantitative data. P-value < 0.05 was considered
statistically significant.
Results
As shown in Fig. 1A and B, we found that IL-17A alone, insulin alone, or IGF1 alone only
slightly induced expression of Cxcl1 and Ccl20, two of the IL-17-downstream target genes,
in the Gsk3b+/+ MEF cells. A combination of IL-17A and insulin (or IGF1), however,
significantly increased the mRNA levels of Cxcl1 and Ccl20 (P < 0.05) (Fig. 1A,B). The
classic GSK3 inhibitor LiCl also enhanced IL-17-induced gene expression (Fig. 1C). To
determine if GSK3B was involved, we performed the same experiments in the Gsk3b−/−
MEF cells. We found that, in the absence of GSK3B, IL-17A alone induced more than 20-
fold higher levels of Cxcl1 and more than 5-fold higher levels of Ccl20 in the Gsk3b−/−
MEF cells, compared to the Gsk3b+/+ MEF cells (Fig.1D-F versus A-C). When insulin,
IGF1, or LiCl was combined with IL-17A, they did not further enhance IL-17-induced
expression of Cxcl1 and Ccl20 in the Gsk3b−/− MEF cells (Fig. 1D-F), suggesting that
GSK3B is required to mediate the synergy between insulin/IGF1 and IL-17A.
We next assessed the signaling pathways activated by insulin and IGF1 in the Gsk3b−/− and
Gsk3b+/+ MEF cells. We found that insulin increased phosphorylated Akt (P-Akt at serine
473) from 0.5 to 4 hours in the Gsk3b−/− MEF cells, whereas P-Akt levels were slightly
lower in the Gsk3b+/+ MEF cells (Fig. 2A). This slight difference between the two cell lines
was reflected in P-GSK3A (at serine 21) levels. Nevertheless, we confirmed that GSK3B
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protein was not expressed in the Gsk3b−/− MEF cells and P-GSK3B (at serine 9) was only
increased by insulin in the Gsk3b+/+ MEF cells (Fig. 2A). We found that insulin alone did
not increase P-IκBα levels in either the Gsk3b−/− or Gsk3b+/+ MEF cells. Although the
basal levels of ERK1/2 and P-ERK1/2 were slightly higher in the Gsk3b+/+ MEF cells than
the Gsk3b−/− MEF cells, insulin did not increase P-ERK1/2 levels in either cell line (Fig.
2A). We found that insulin only slightly increased P-STAT3 (Signal transducer and activator
of transcription 3) levels from 1 to 4 hours in the Gsk3b+/+ but not the Gsk3b−/− MEF cells
(Fig. 2A). IGF1 increased P-Akt and P-GSK3A levels to the same magnitude in both
Gsk3b−/− and Gsk3b+/+ MEF cells, but only increased P-GSK3B levels in the Gsk3b+/+
MEF cells (Fig. 2B). IGF1 did not increase P-IκBα, P-ERK1/2, or P-STAT3 levels in either
Gsk3b−/− or Gsk3b+/+ MEF cells (Fig. 2B). These findings suggest that insulin and IGF1
activate Akt pathway in both Gsk3b−/− and Gsk3b+/+ MEF cells, which inactivates GSK3B
through phosphorylation at serine 9 in the Gsk3b+/+ MEF cells.
Since we observed that IL-17A alone dramatically increased expression of Cxcl1 and Ccl20
in the Gsk3b−/− but not the Gsk3b+/+ MEF cells, we investigated the differences in IL-17-
activated NF-κB and ERK1/2 pathways. We found that IL-17A dramatically increased the
P-IκBα levels at 0.5 to 1 hour in the Gsk3b−/− MEF cells, whereas such an increase was
absent in the Gsk3b+/+ MEF cells (Fig. 3A). The increase of P-IκBα was accompanied by a
decrease of IκBα, implicating that NF-κB is released from the NF-κB:IκBα complex and
becomes activated. There were not any obvious changes in NF-κB p65 (RELA) levels after
IL-17A treatment (Fig. 3A). On the other hand, there was not much difference in IL-17A-
induced activation of P-ERK1/2 between the Gsk3b−/− and Gsk3b+/+ MEF cells, except that
there was a little higher level of P-ERK2 at 2 hours in the Gsk3b−/− MEF cells than the
Gsk3b+/+ MEF cells (Fig. 3A). No increase of P-Akt levels was observed in either Gsk3b−/−
or Gsk3b+/+ MEF cells. These findings suggest that, in the absence of GSK3B, IL-17A
stimulates higher levels of NF-κB activation to transcribe the downstream genes. To
examine whether the enhanced NF-κB activity is specific to IL-17 signaling, we treated the
MEF cells with TNFα, a classic activator of NF-κB pathway. We found that TNFα induced
similar time-dependent changes of P-IκBα and IκBα in both Gsk3b−/− and Gsk3b+/+ MEF
cells, without any changes in NF-κB p65 (RELA) levels (Fig. 3B). These findings suggest
that GSK3B negatively regulates IL-17-induced phosphorylation of IκBα, but not TNFα-
induced phosphorylation of IκBα.
Since phosphorylation of GSK3B at serine 9 inhibits GSK3B activity, melatonin can
enhance GSK3B activity through decreasing P-GSK3B at serine 9. Having shown that
GSK3B is a negative regulator of IL-17 signaling, we tested if melatonin could inhibit
IL-17-induced gene expression through enhancing GSK3B. We found that melatonin
inhibited IL-17A-induced Cxcl1 expression in the Gsk3b+/+ MEF cells (Fig. 4A). Melatonin
did not inhibit IL-17A-induced expression of Cxcl1 and Ccl20 in the Gsk3b−/− MEF cells
(Fig. 4B), suggesting that melatonin's action is mediated by GSK3B. Further, we found that,
although IL-17A did not activate Akt, melatonin reduced the basal levels of P-Akt and Akt,
thus reduced the level of P-GSK3B at serine 9 in the Gsk3b+/+ MEF cells (Fig. 4C). The
basal levels of P-STAT3 were not affected by melatonin (Fig. 4C), suggesting that
melatonin's effect is specific to the Akt-GSK3B pathway.
Since insulin activates PI3K/Akt pathway to inhibit GSK3B activity and subsequently
enhance IL-17-induced gene expression, we tested if melatonin could antagonize insulin's
action by inhibiting Akt activation. We found that melatonin indeed significantly reduced
the mRNA levels of Cxcl1 and Ccl20 that were induced by a combination of insulin and
IL-17A in the Gsk3b+/+ MEF cells (P < 0.05) (Fig. 5A). Since melatonin did not show any
effects in the Gsk3b−/− MEF cells (Fig. 5B), it suggests that melatonin's action is dependent
on GSK3B. In order to rule out the possibility that 10 nM melatonin is not sufficient to
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inhibit IL-17A's effects in the Gsk3b−/− MEF cells, we treated the cells with 500 nM of
melatonin. We found that 500 nM of melatonin significantly inhibited induction of Cxcl1
and Ccl20 by insulin and IL-17A in the Gsk3b+/+ MEF cells (P < 0.05) (Fig. 5C), but this
high dose of melatonin still had no effects in the Gsk3b−/− MEF cells (Fig. 5D). These
findings further confirm that melatonin's action is GSK3B-dependent.
We tested if our findings obtained from the cultured MEF cell lines would be reproducible
in mouse prostatic tissues. We harvested fresh mouse prostatic glandular tissues and treated
them in the ex vivo cultures. We found that IL-17A alone significantly induced expression
of Cxcl1, Ccl20 and Il-6 in the mouse prostatic tissues (P < 0.05, compared to the control
group) and a combination of insulin and IL-17A induced expression of these genes to
significantly higher levels (P < 0.01, compared to the IL-17A alone group) (Fig. 6A).
Melatonin significantly reduced expression of these genes that was induced by insulin and
IL-17A (P < 0.01, compared to the insulin + IL-17A group) (Fig. 6A). These findings
suggest that insulin can enhance IL-17-induced gene expression in the mouse prostatic
tissues, which can be antagonized by melatonin.
We found that the nighttime blood significantly reduced expression of Cxcl1, Ccl20, and
Il-6 in the xenograft tumor tissues, compared to the tumor tissues perfused with the daytime
blood (P < 0.05) (Fig. 6B). On the other hand, the levels of gene expression in the tumor
tissues perfused with the light-at-night blood were moderate compared to the daytime blood
and nighttime blood groups (Fig. 6B). Since the blood contains many other factors that may
regulate expression of the genes examined, we did two additional experiments to assess if
the observed changes in gene expression were dependent on melatonin. First, we added
melatonin receptor antagonist S20928 to the nighttime blood. As expected, addition of
S20928 significantly increased the levels of gene expression (P < 0.05), compared to the
nighttime blood group (Fig. 6B). Next, we added melatonin to the light-at-night blood. We
found that addition of melatonin significantly reduced expression of Cxcl1 and Ccl20 (P <
0.05), compared to the light-at-night blood alone group (Fig. 6B). Collectively, these
findings suggest that physiological levels of melatonin in the nighttime blood decrease
expression of IL-17-downstream target genes in the tissue-isolated PC3 human prostate
cancer xenografts.
Discussion
Melatonin has been shown to reduce mRNA levels of IL-6, IL-1β, TNF-α, and matrix
metalloproteinase-9 (MMP-9) in the rabbit liver infected with rabbit hemorrhagic disease
viruses, thus attenuating inflammation and promoting liver regeneration [41]. Melatonin has
also been demonstrated to reduce methamphetamine-induced overexpression of IL-6, IL-1β,
and TNF-α in microglial cell lines [42]. It is known that IL-17 cytokine induces expression
of proinflammatory chemokines, cytokines, growth factors, and MMPs, including IL-6,
IL-1β, TNF-α, and MMP-9 [7, 43]. Therefore, we were prompted to investigate if melatonin
can regulate IL-17-induced expression of chemokines and cytokines.
IL-17 acts on the IL-17RA/IL-17RC receptor complex to recruit Act1 and then TRAF6,
leading to activation of TAK1 and IKK kinases, thus IκBα is phosphorylated and degraded.
Subsequently, NF-κB is released from the NF-κB:IκBα complex and enters into the nucleus
to initiate transcription of downstream target genes [44]. In addition, IL-17 activates
ERK1/2 pathway and Act1-TRAF2-TRAF5-SF2/ASF complex to stabilize the mRNAs of
IL-17-downstream target genes [22-24]. Thus, IL-17 increases the expression levels of the
downstream target genes through mechanisms of transcription and mRNA stabilization via
distinct signaling pathways (Fig. 7).
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In this study, we demonstrated that insulin and IGF1 enhance IL-17-induced expression of
chemokines (Cxcl1 and Ccl20) and cytokine (Il-6). Insulin and IGF1 mainly act through the
PI3K/Akt pathway to inhibit GSK3B activity by phosphorylation of GSK3B at serine 9, as it
has been shown that phosphorylation of GSK3B at serine 9 decreases GSK3B enzyme
activity [27, 28]. We also demonstrated that the crosstalk between insulin/IGF1 and IL-17
signaling pathways is dependent on GSK3B. We provided three lines of evidence to support
this concept: first, the synergy between insulin/IGF1 and IL-17 is only found in the Gsk3b
wild-type MEF cells, which is abolished in the Gsk3b knockout MEF cells; second, the
synergy between GSK3 inhibitor LiCl and IL-17 is only found in the Gsk3b wild-type MEF
cells, which is also abolished in the Gsk3b knockout MEF cells; and third, melatonin, an
activator of GSK3B activity, can only inhibit the synergistic action of insulin and IL-17 in
the Gsk3b wild-type MEF cells, but not in the Gsk3b knockout MEF cells.
GSK3B has been shown to act as a negative regulator of IL-17 signaling in the previous
study [32]. The mechanism of GSK3B's inhibitory action on IL-17 signaling has been
proposed as that GSK3B phosphorylates C/EBPβ at threonine 179 after C/EBPβ is
phosphorylated at threonine 188 by ERK1/2, thereby the phosphorylated C/EBPβ inhibits
the transcription function of the unphosphorylated C/EBPβ [32] (Fig. 7). In addition, it is
possible that GSK3B may act on other unknown substrates to inhibit IL-17 signaling. For
example, we demonstrated that Gsk3b knockout increases the levels of P-IκBα induced by
IL-17A (Fig. 3A), suggesting that GSK3B may negatively regulate IL-17 signaling at the
level of IKK or above in the signaling cascade (Fig. 7). Recently, it has been shown that
GSK3B phosphorylates C/EBPδ at threonine 156, leading to degradation of C/EBPδ, thus
attenuating Toll-like receptor 4-induced inflammation-associated genes in macrophages and
tumor cells [45]. Given that IL-17 induces expression of C/EBPδ [9, 20, 30] and C/EBPδ is
essential for transcription of IL-17-downstream target genes such as IL-6 and 24p3/lipocalin
2 [31], it is intriguing to investigate whether the GSK3B-C/EBPδ mechanism mediates
GSK3B's inhibitory action in IL-17 signaling in future studies.
Two main implications of this study are identified. First, the synergy between insulin/IGF1
and IL-17 may explain the chronic inflammatory status found in obesity. It is known that
obese people have increased serum levels of insulin and IGF1[34] and IL-17 [37]. Based on
the current study, insulin and IGF1 can enhance IL-17-induced proinflammatory
chemokines and cytokines, thus the increased levels of insulin, IGF1, and IL-17 may act
together to build up the chronic inflammatory status in obesity. This is consistent with the
findings that many of the obesity-associated inflammatory cytokines/chemokines are IL-17-
downstream target genes, including IL-6, IL-8, IL-1β, TNFα, vascular endothelial growth
factor, CCL2, and CCL5 [46]. Second, the synergy between insulin/IGF1 and IL-17 can be
inhibited by melatonin. We found that melatonin at pharmacological concentrations (10 to
500 nM) inhibited chemokine expression induced by insulin and IL-17 in the cultured MEF
cells and mouse prostatic tissues. We and other investigators have previously shown that
human serum melatonin concentrations can reach 500 nM by oral administration of 80 mg
melatonin or intravenous administration of 2 mg melatonin [47, 48]. Further, we found that
melatonin at physiological concentrations inhibited chemokine expression in the tissue-
isolated PC3 human prostate cancer xenografts. The nighttime blood significantly reduced
expression of Cxcl1, Ccl20, and Il-6 in the xenograft tumor tissues, compared to the tumor
tissues perfused with the daytime blood. In contrast, the levels of gene expression in the
tumor tissues perfused with the light-at-night blood were moderate compared to the daytime
blood and nighttime blood groups. These findings are consistent with the blood levels of
melatonin, that is, the lowest in the daytime blood, the highest in the nighttime blood, and
intermediate in the light-at-night blood [40]. Of note, because we used the archived tumor
samples, we were unable to retrospectively measure the levels of insulin and IL-17 in the
blood samples that were used in perfusion of the tumors. Nevertheless, we speculate that the
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physiological levels of insulin and IL-17 might exist in the blood samples [49, 50]. To our
best knowledge, this is the first time that melatonin is found to inhibit IL-17-mediated
inflammation through enhancing GSK3B activity.
Obesity has been associated with many co-morbidities, including type 2 diabetes and several
cancers [34]. Light-at-night-induced suppression of melatonin production has been shown to
contribute to obesity [51]. In a rabbit model of high-fat diet-induced obesity, intake of
melatonin is associated with reduction of food consumption and weight gain, lowering of
blood pressure and heart rate, and decrease of blood glucose and lipids [52]. In a rat model
of high-calorie diet-induced obesity, melatonin treatment reduces weight gain, visceral
adiposity, and serum levels of insulin and triglycerides [53]. In male young Zucker diabetic
fatty rats, melatonin reduces weight gain, serum triglyceride level, and low-density-
lipoprotein cholesterol, but increases high-density-lipoprotein cholesterol [54]. Furthermore,
melatonin significantly reduces the plasma levels of IL-6 and TNF-α in Zucker diabetic fatty
rats [55], though it is not clear if the reduction of IL-6 and TNF-α is mediated through
inhibition of IL-17 signaling. Based on the findings in the present study and aforementioned
previous studies, we speculate that melatonin is potentially able to dampen the inflammatory
status in obesity. In conclusion, the present study has demonstrated that insulin and IGF1
enhance IL-17-induced expression of inflammatory chemokines/cytokines through a
GSK3B-dependent mechanism, which can be inhibited by melatonin. The anti-inflammatory
actions of melatonin may be utilized to treat obesity-associated chronic inflammation and
co-morbidities such as type 2 diabetes and cancer.
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Insulin, IGF1, and LiCl enhanced IL-17-induced chemokine expression in the Gsk3b+/+
MEF cells, but not in the Gsk3b−/− MEF cells. (A-C) Gsk3b+/+ MEF cells. (D-F) Gsk3b−/−
MEF cells. Insulin (10 nM), IGF1 (50 ng/ml), or LiCl (20 mM) was added 30 min prior to
addition of IL-17A (20 ng/ml). Two hours after IL-17A treatment, the relative mRNA levels
of Cxcl1 and Ccl20 were determined by qRT-PCR. The data are presented as mean ±
standard deviation of three experiments. aP < 0.05, compared to the IL-17A alone group.
When compared to the untreated control group, only the combined treatment groups showed
P < 0.05 in panels A to C; the IL-17A alone groups and the combined treatment groups
showed P < 0.05 in panels D to F; the other treatment groups showed P > 0.05 in panels A to
F.
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Effects of insulin and IGF1 on intracellular signaling pathways. The Gsk3b−/− and Gsk3b+/+
MEF cells were treated with 10 nM insulin (A) or 50 ng/ml IGF1 (B) for the indicated time.
The levels of phosphorylated and unphosphorylated proteins were determined by Western
blot analysis. Equal loading of proteins was confirmed by reprobing the blot for GAPDH.
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Gsk3b knockout enhanced phosphorylation of IκBα induced by IL-17 but not by TNFα. The
Gsk3b−/− and Gsk3b+/+ MEF cells were treated with 20 ng/ml IL-17A (A) or 5 ng/ml TNFα
(B) for the indicated time. The levels of phosphorylated and unphosphorylated proteins were
determined by Western blot analysis. Equal loading of proteins was confirmed by reprobing
the blot for GAPDH.
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Melatonin inhibited IL-17-induced chemokine expression in the Gsk3b+/+ MEF cells but not
in the Gsk3b−/− MEF cells. (A) The Gsk3b+/+ MEF cells or (B) the Gsk3b−/− MEF cells
were treated with 10 nM melatonin 30 min prior to addition of 20 ng/ml IL-17A. Two hours
after IL-17A treatment, the relative mRNA levels of Cxcl1 and Ccl20 were determined by
qRT-PCR. The data are presented as mean ± standard deviation of three experiments. aP <
0.05, compared to the IL-17A alone group. When compared to the untreated control group,
the IL-17A alone group in induction of Cxcl1 in panel A showed P < 0.05; the IL-17A alone
groups and the combined treatment groups in panel B showed P < 0.05; the other treatment
groups showed P > 0.05 in panels A and B. (C) Effects of melatonin on intracellular
signaling pathways: The Gsk3b−/− and Gsk3b+/+ MEF cells were treated with 10 nM
melatonin 30 min prior to addition of 20 ng/ml IL-17A for 2 hours. The levels of
phosphorylated and unphosphorylated proteins were determined by Western blot analysis.
The loading of proteins was confirmed by reprobing the blot for GAPDH.
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Melatonin inhibited the synergy between insulin and IL-17 in induction of Cxcl1 and Ccl20
in the Gsk3b+/+ MEF cells, but not in the Gsk3b−/− MEF cells. The Gsk3b+/+ MEF cells (A
& C) or the Gsk3b−/− MEF cells (B & D) were treated with melatonin (10 nM in A-B, 500
nM in C-D) and/or 10 nM insulin 30 min prior to addition of IL-17A (20 ng/ml in A-B, 100
ng/ml in C-D). Two hours after IL-17A treatment, the relative mRNA levels of Cxcl1 and
Ccl20 were determined by qRT-PCR. The data are presented as mean ± standard deviation
of three experiments. aP < 0.05, compared to the insulin + IL-17A group. When compared to
the control group, the insulin + IL-17A groups in panels A and C showed P < 0.05; the
IL-17A alone group in induction of Cxcl1 in panel C showed P < 0.05; the IL-17A alone
groups, the insulin + IL-17A groups, and melatonin + insulin + IL-17A groups in panels B
and D showed P < 0.05; the other treatment groups showed P > 0.05 in panels A to D.
Ge et al. Page 17














Melatonin inhibited expression of IL-17-downstream target genes in mouse prostatic tissues
and PC3 human prostate cancer xenograft tumors. (A) The ex vivo cultured mouse prostatic
tissues were treated with 10 nM insulin and/or 10 nM melatonin 30 min prior to addition of
20 ng/ml IL-17A. Two hours after IL-17A treatment, the relative mRNA levels of Cxcl1,
Ccl20, and Il-6 were determined by qRT-PCR. The data are presented as mean ± standard
deviation of three experiments. aP < 0.05, compared to the control group; bP < 0.01,
compared to the IL-17A alone group; cP < 0.01, compared to the insulin + IL-17A group.
(B) The PC3 human prostate cancer xenograft tumors were perfused in situ with the daytime
blood, nighttime blood, light-at-night blood, nighttime blood supplemented with 1 nM of
melatonin receptor antagonist S20928, or light-at-night blood supplemented with 500 pM of
melatonin, for 1 hour. The relative mRNA levels of Cxcl1, Ccl20, and Il-6 were determined
by qRT-PCR. The data are presented as mean ± standard deviation of three tumors. aP <
0.05, compared to the daytime blood group; bP < 0.05, compared to the nighttime blood
group; cP > 0.05, compared to the nighttime blood group.
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Illustration of the proposed mechanisms underlying the crosstalk between insulin/IGF1 and
IL-17 signaling pathways. IL-17 acts on the IL-17RA:IL-17RC receptor complex to activate
Act1-TRAF6-TAK1-IKK signaling cascade, thus activating NF-κB and C/EBPβ
transcription factors for initiation of transcription of the downstream target genes. In
addition, IL-17 activates ERK1/2 and Act1-TRAF2-TRAF5-SF2/ASF complex to stabilize
mRNAs. Insulin and IGF1 activate PI3K/Akt pathway through their receptors; Akt
phosphorylates GSK3B at serine 9 to inhibit GSK3B enzyme activity; GSK3B
phosphorylates C/EBPβ at threonine 179 after a priming phosphorylation at threonine 188
by ERK1/2, thus inhibiting C/EBPβ's transcription function. Therefore, insulin/IGF1
signaling is linked with IL-17 signaling by GSK3B and C/EBPβ. Melatonin inhibits Akt
activation, thus enhancing GSK3B activity and subsequently diminishing IL-17-induced
gene expression by inhibiting C/EBPβ function.
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